TAKARA BIO INC.

2008.04.30: Start of clinical research of cancer immunotherapy using RetroNectin^® expansion culture system at Tianjin Cancer Institute & Hospital, China [New!]
2008.01.22: MolMed S.p.A., a strategic partner of Takara Bio in gene therapy, obtains a regulatory approval to start a Phase III trial of HSV-TK gene therapy for high risk acute leukemia in Italy
2008.01.09: Takara Bio to enter into an M-CRADA with Dr. Rosenberg's group at NCI initiating pre-clinical studies of gene therapy using RetroNectin^®-expansion culture system
2007.07.19: Takara Bio Grants Kemp Biotechnologies a license for LA-PCR Technology
2007.05.07: Takara Bio Grants Transgenomic a license for LA-PCR Technology